Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562

Nehad M. El-Dydamonya Pharmaceutical Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, EgyptCorrespondence[email protected]

Rana M. Abdelnabyb Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt

Rasha Abdelhadyc Pharmacology and Toxicology Department, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt

Omaima Alid Cell Line Unit, Egyptian Drug Authority (EDA), Cairo, Egypt

Mohamed I. Fahmye Pharmacology and Toxicology Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt

Rasha R. Fakhr Eldeenf Biochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, Egypt

Amira A. Helwag Pharmaceutical Organic Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, Egypt

show all

Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date